Likewise, as reported with other irAEs, a combined ICI therapy with anti-CTLA4 and anti-PD-1/PD-L1, significantly increases the risk of developing an immune-related CE (22), as well as previous administration of other cardiotoxic cancer therapies, such as anthracyclines, trastuzumab, thoracic radiotherapy, or antiangiogenic therapy. Here, CTLA4 is linked to cancer.